Orthofix Medical (NASDAQ:OFIX) Announces Quarterly Earnings Results, Misses Estimates By $0.40 EPS

Key Points

• Orthofix Medical reported a quarterly EPS of ($0.36), missing analysts' estimates by $0.40 and reflecting a negative return on equity of 28.15% and net margin of 17.78%.
• The company's stock, trading at $12.18, has seen a rise of 12.2% recently, while analysts maintain a consensus target price of $21.50 and a "Moderate Buy" rating.
• Insider trading activity included a sale of 3,728 shares by a company insider and a purchase of 10,000 shares by CEO Massimo Calafiore, indicating mixed confidence among company insiders.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) posted its quarterly earnings results on Tuesday. The medical device company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40), Zacks reports. Orthofix Medical had a negative return on equity of 28.15% and a negative net margin of 17.78%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Trading Up 12.2%

NASDAQ:OFIX traded up $1.33 during midday trading on Tuesday, reaching $12.18. 447,537 shares of the stock traded hands, compared to its average volume of 309,790. The stock has a market capitalization of $477.02 million, a P/E ratio of -3.30 and a beta of 0.82. Orthofix Medical has a 12 month low of $10.24 and a 12 month high of $20.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.71. The company has a fifty day moving average of $11.02 and a 200 day moving average of $14.03.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen cut Orthofix Medical from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Finally, Barrington Research raised Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective for the company in a report on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $21.50.

Insider Activity

In related news, insider Aviva Mcpherron sold 3,728 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the completion of the transaction, the insider owned 46,322 shares in the company, valued at $486,844.22. This represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Massimo Calafiore acquired 10,000 shares of the firm's stock in a transaction on Friday, May 9th. The stock was bought at an average price of $12.54 per share, with a total value of $125,400.00. Following the completion of the acquisition, the chief executive officer directly owned 234,603 shares in the company, valued at approximately $2,941,921.62. This represents a 4.45% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 113,500 shares of company stock valued at $1,394,858. Insiders own 1.30% of the company's stock.

Institutional Trading of Orthofix Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio bought a new position in shares of Orthofix Medical during the first quarter valued at $150,000. AQR Capital Management LLC lifted its position in Orthofix Medical by 67.7% in the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock valued at $333,000 after acquiring an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock valued at $335,000 after purchasing an additional 1,213 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Orthofix Medical in the first quarter worth $1,076,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.